The serotonin syndrome: Definition and eause

Nordic Journal of Psychiatry

Volumn 50, Issue 3, 1996, Pages 249-260

  Laier, Gro ^a  

^a Sundhedsstyrelsen   (Denmark)

Author keywords

Antidepressants; Neuroleptic malignant syndrome; Pathogenesis; Serotonin syndrome; Toxic reaction

Indexed keywords

DOPAMINE; FLUOXETINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; SEROTONIN; SEROTONIN AGONIST;

ANXIETY; ARTICLE; BRAIN STEM; CENTRAL NERVOUS SYSTEM DISEASE; DIAPHORESIS; DRUG ELIMINATION; FEVER; HUMAN; INTENSIVE CARE; INTUBATION; MYOCLONUS; NERVE STIMULATION; NEUROLEPTIC MALIGNANT SYNDROME; PARALYSIS; PATHOGENESIS; RESTLESSNESS; SPINAL CORD;

EID: 0029995866     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039489609081415     Document Type: Article

References (53)

1. Braitberg G. Serotonin syndrome. Med J Aust 1994; 160: 527 – 8
2. Kline S. S., Mauro L. S., Scala-Barnett D. M., Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989; 8: 510 – 4
3. Lenzi A., Raffaelli S., Marazziti D. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder; following inappropriate increase in fluvoxamine dosage. Pharmacopsych 1993; 26: 100 – 1
4. Lejoyeux M., Fineyre F. The serotonin syndrome. Am J Psychiatry 1992; 149: 1410 – 1
5. Price L. H., Charney D. Serotonin syndrome. Am J Psychiatry 1992; 149: 1116 – 7
6. Ooi T. K. The serotonin syndrome. Anaesthesia 1991; 46: 507 – 8
7. Halman M., Goldbloom D. S. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990; 28: 518 – 21
8. Goldberg R. J., Huk M. Serotonin syndrome from traxodone and buspirone. Psychosomatics 1992; 33: 235 – 6
9. Dursun M. S., Mathew V. M., Reveley M. A. Toxic serotonin syndrome after fluoxetine plus carbamaze-pine. Lancet 1993; 342: 442 – 3
10. Baloh R. W., Dietz J., Spooner J. W. Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol 1982; 11: 95 – 7
11. Insel T. R., Roy B. V., Cohen R. M., Murphy D. L. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139: 954 – 5
12. Thomas J. M., Rubin E. H. Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatry 1984; 141: 281 – 3
13. Pope H. G., Jonas J. M., Hudson J. T., Kafka M. P. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptohan. Am J Psychiatry 1985; 142: 491 – 2
14. Levy A. B., Bucher P., Votolato N. Myoclonus hy-perreflexia and diaphoresis in patient on phenelzine-tryptophan combination treatment. Can J Psychiatry 1985; 30: 434 – 6
15. Guze B. H., Baxter LR, Jr. The serotonin syndrome: case responsive to propranolol. J Clin Psychophar-macol 1986; 6: 119 – 20
16. Price W. A., Zimmer B., Kucas P. Serotonin syndrome: A case report. J Clin Pharmacol 1986; 26: 77 – 8
17. Steiner W., Fontaine R. Toxic reaction following the combined administration fluoxetine and L-tryptophan: Five case reports. Biol Psychiatry 1986; 21: 1067 – 71
18. Sandyk R. L-Dopa induced serotonin syndrome- in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 1986; 6: 194 – 5
19. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2: 850
20. Feighner J. P., Boyer W. F., Tyler D. L., Neborsky R. J. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222 – 5
21. Klee B., Kronig M. H. Case report of probable sertra-line-induced akathisia. Am J Psychiatry 1993; 150: 986 – 7
22. Brennan D., Manus M. M., Howe J., McLoughlin J. Neuroleptic malignant syndrome without neuroleptics. Br J Psychiatry 1988; 152: 578 – 9
23. Spigset O., Mjömdal T., Lövheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993; 306: 248
24. Muly C. E., McDonald W., Steffens D., Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry 1993; 150: 1565
25. Nierenberg D. W., Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993; 53: 84 – 8
26. Nimmo S. M., Kennedy B. W., Tullett W. M., Blyth A. S., Dougall J. R. Drug-induced hyperthermia. Anaesthesia 1993; 48: 892 – 5
27. Neuvonen J. P., Pohjola-Sintonen, Tacke U., Vuori E. Five fatal cases of serotonin syndrome after moc-lobemide—citalopram or moclobemide—clomipramine overdose. Lancet 1993; 342
28. Brodribb T. R., Downey M., Gilbar P. J. Efficacy and adverse effects of moclobemide. Lancet 1994; 343: 475
29. öhman R., Spigest O. Serotonin syndrome induced by fluvoxamine—lithium interaction. Pharmaco-psychiat 1993; 26: 263 – 4
30. Kojima H., Terao T., Yoshimura R. Serotonin syndrome during clomipramine and lithium treatment. Am J Psychiatry 1993; 150: 1897
31. Coplan J. D., Gorman J. M. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 1993; 150: 837
32. Hernandez A., Montero M. N., Pla A., Villanueva E. Fatal moclobemide overdose or death caused by serotonin syndrome. J Foren Sci 1995; 40: 128 – 30
33. Graber M. A., Hoehns T. B., Perry P. J. Sertraline -phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 1994; 28: 732 – 5
34. Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983 – 5
35. Jahr J. S., Pisto J. D., Gitlin M. The Serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg 1994; 79: 189 – 91
36. Karle J., Bjørndal F. Serotonergt syndrom. Ugeskr Laeger 1994; 157: 1204 – 5
37. Brannan S. K., Talley B. J., Bowden C. L. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 1994; 14: 144 – 5
38. Kaminsk C. A., Robbins M. S., Weibley R. E. Sertraline intoxication in a child. Ann Emerg Med 1994; 23: 1371 – 4
39. Lappin R. I., Auchincloss E. L. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 331: 1021 – 2
40. Reeves R. R., Bullen J. A. Serotonin syndrome produced by paroxetin and low-dose trazodone. Psyc-homatics 1995; 36: 159 – 60
41. Cano-Muñox J. L., Montejo-Iglesias M. L., Yañez-Saez, Gálvez-Borrero I. M. Possible serotonin syndrome following the combined administration of clomipramine and alprazolam. J Clin Psychiatry 1995; 56: 122
42. Skop B. P., Finkelstein J. A., Mareth T. R., Magoon M. R., Brown T. M. The serotonin syndrome associated with paroxetine, an over-the counter cold remedy, and vascular disease. Am J Emerg Med 1994; 12: 642 – 4
43. Heyland D., Sauvé M. Neuroleptic malignant syndrome without the use of neuroleptics. Can Med Assoc J 1991; 145: 817 – 9
44. Persson R. Serotonergt syndrom—en fallbeskrivn-ing. Nord J Psychiatry 1992; 46: 117 – 9
45. Bodner R. A., Lynch T., Lewis L., Kahn D. Serotonin syndrome. Neurology 1995; 45: 219 – 33
46. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705 – 13
47. Becker T., Komhuber J., Hofmann E., Weller M., Rupprecht C., Beckmann H. MRI white matter hy-perintensity in neuroleptic malignant syndrome (NMS)—a clue to pathogenesis. J Neural Transm [GenSect] 1992; 90: 151 – 9
48. Ishiguro T., Nisijima K. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobuty-ric acid in neuroleptic malignant syndrome. XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress. Neuropsycho-pharmacology 1994; 10 (No. 3S/Part 1) 462S, ISSN 0893–133X.
49. Yamawaki S., Hayashi T. Intercellular calcium mechanism in the pathogenesis of neuroleptic malignant syndrome. XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress. Neu-ropsychopharmacology 1994; 10 (No. 3S/Part 1) 465S, ISSN 0893–133X.
50. Henry J. A. Serotonin syndrome. Lancet 1994; 343: 607
51. Lucimey L., Salazar M., Trejo E. Modulation of 5HTIA receptors in the rats treated with clonazepam. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 663 – 77
52. Lucimey L. Region-selective reduction of brain serotonin turnover rate and serotonin agonist-induced behavior in mice treated with clonazepam. Pharmacol Biochem Behav 1990; 39: 671 – 6
53. Leonard H. L., Topol D., Bukstein O., Hindmarsh D., Allan A. J., Swedo S. E. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994; 33: 792 – 4